DMAC at a glance
DiaMedica Therapeutics Inc. (DMAC, SEC CIK 1401040) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as August 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 20 institutional investment managers tracked by SignalX reported holding DiaMedica Therapeutics Inc. (DMAC) shares worth $44.7 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 20 funds
- $44.7M · −1 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, with no product sales
- R&D expenses $9.2M vs $6.4M YoY, G&A expenses $2.4M vs $2.6M
- Net loss $31.5M for nine months vs $24.0M YoY, no margin figures disclosed
- Cash, equivalents and securities $34.9M vs $59.9M at December 31, 2025
- ReMEDy2 enrollment slower than expected, interim results expected by end of Q1 2027; additional funding anticipated
Risk Factors
- No material changes to previously disclosed risk factors in the December 31, 2025 Form 10-K
- Carried-forward risk: unknown or currently immaterial risks could impair business, financial condition, or results of operations
- Carried-forward disclosure: existing uncertainties could cause actual results to differ materially from forward-looking statements
AI summary of the DMAC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full financial results and management commentary available in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- FGR enrollment complete for first two cohorts, 12 participants at 5 and 10 µg/kg, with preliminary topline results scheduled November 24
- ReMEDy2 stroke trial exceeded 200 participants, enabling DSMB interim analysis after 90-day follow-up, expected Q1 2027
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Full condensed financial results available in Exhibit 99.1, relevant for assessing liquidity and operating performance
Item EX-99.1: Item EX-99.1
- Q2 net loss $10.1M, up from $7.7M, with R&D expense rising to $8.2M from $5.8M
- Cash, equivalents and investments $43.5M, down from $59.9M at December 31, 2025, supporting planned operations through 2027
Item 5.07: Submission of Matters to a Vote of Security Holders
- All seven incumbent directors re-elected, preserving board continuity through the next annual meeting
- Baker Tilly US, LLP ratified as independent auditor for fiscal 2026, with shareholders authorizing board-set remuneration
AI summaries of DMAC 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DMAC
Don't miss the next DMAC filing
- Alerts as it files. A push when DMAC files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DMAC, by share count.
- Ask anything. An AI agent that reads every DMAC filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Pauls Dietrich John | A | Aug 10, 2026 | 60,200 | - |
| Kellen Scott | A | Jun 1, 2026 | 162,000 | - |
| Parsons James T. | A | Jun 1, 2026 | 51,189 | - |
| Giuffre Randall Michael | A | Jun 1, 2026 | 40,412 | - |
| Kuntz Richard | A | Jun 1, 2026 | 40,412 | - |
| Krop Julie | A | Jun 1, 2026 | 67,500 | - |
| Lewis Tanya | A | Jun 1, 2026 | 40,412 | - |
| O'Connor Daniel J. | A | Jun 1, 2026 | 40,412 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$21.3M | -$26.7M | -$34.4M |
| Net Income | -$19.4M | -$24.4M | -$32.8M |
| Balance Sheet | |||
| Total Assets | $54.2M | $46.3M | $61.4M |
| Equity | $51.1M | $40.7M | $56.1M |
| ROE | -38.0% | -60.0% | -58.4% |
| Per Share | |||
| EPS | - | $-0.60 | $-0.70 |
| Cash Flow | |||
| Operating CF | -$18.7M | -$22.1M | -$29.1M |
| CapEx | $24K | $25K | $40K |
Source: XBRL data in DiaMedica Therapeutics Inc. (DMAC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate DMAC share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 20 | $44.7M |
| Q2 2026 | 21 | $37.8M |
| Q1 2026 | 22 | $33.5M |
| Q4 2025 | 20 | $43.6M |
| Q3 2025 | 20 | $36.5M |
| Q2 2025 | 16 | $14.6M |
| Q1 2025 | 12 | $8.6M |
| Q4 2024 | 8 | $9.0M |
- Citadel Advisors LLC+39.1K (+27%)
- Morgan Stanley+24.2K (+52%)
- Bank of America Corp+19.7K (+34%)
- Goldman Sachs Group+19.4K (+12%)
- State Street Corp+13.0K (+2%)
- BlackRock−43.0K (-2%)
- Wells Fargo & Co−22.3K (-60%)
- Citigroup−15.4K (-89%)
- Millennium Management−14.2K (-2%)
- Northern Trust−1.2K (-0%)
- FMR LLC (Fidelity)−8.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 139 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DMAC filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 4 | Aug 12, 2026 | - | - | - |
| 10-Q | Aug 10, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 8-K | May 21, 2026 | - | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Mar 31, 2026 | - | - | - |
| 10-K | Mar 30, 2026 | Dec 31, 2025 | - | |
| 4 | Jan 6, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - | |
| 4 | Jan 6, 2026 | - | - | |
| 8-K | Jan 5, 2026 | - | - | |
| 8-K | Dec 18, 2025 | - | - | |
| 4 | Dec 8, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
DMAC SEC filings: frequently asked questions
Which institutions hold DMAC stock?
As of September 30, 2026, the largest DiaMedica Therapeutics Inc. (DMAC) holders among the 13F filers tracked by SignalX were BlackRock ($18.3 million), Millennium Management ($6.9 million), State Street Corp ($5.5 million), Vanguard Capital Management LLC ($3.0 million), Northern Trust ($2.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did DMAC report in its latest 8-K?
DiaMedica Therapeutics Inc. (DMAC) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.
What are the latest DMAC SEC filings?
DiaMedica Therapeutics Inc. (DMAC) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on August 12, 2026.
What is DMAC's SEC CIK number?
DiaMedica Therapeutics Inc. (DMAC)'s SEC Central Index Key (CIK) is 1401040. EDGAR lists every DMAC filing under that number.
Ask anything about DMAC
The research agent reads DMAC's filings, financials, insider trades and 13F holders, then answers with sources.